ILS-920

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C57H86N2O14
Molecular Weight	1023.2977
Optical Activity	UNSPECIFIED
Defined Stereocenters	17 / 17
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)[C@]4([H])CC[C@@]([H])(ON4C5=CC=CC=C5)\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]6CC[C@@H](O)[C@@H](C6)OC

InChI

InChIKey=WZFNBQBUDJACCD-ZSYWEHCUSA-N

InChI=1S/C57H86N2O14/c1-33-26-37(5)51(62)53(70-10)52(63)38(6)27-34(2)47(61)32-49(35(3)28-40-20-24-46(60)50(30-40)69-9)71-56(66)45-18-14-15-25-58(45)55(65)54(64)57(67)39(7)19-21-42(72-57)31-48(68-8)36(4)29-43-22-23-44(33)59(73-43)41-16-12-11-13-17-41/h11-13,16-17,27,29,33-35,37,39-40,42-46,48-50,52-53,60,63,67H,14-15,18-26,28,30-32H2,1-10H3/b36-29+,38-27+/t33-,34+,35+,37+,39+,40-,42-,43+,44-,45-,46+,48-,49-,50+,52+,53-,57+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C57H86N2O14
Molecular Weight	1023.2977
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	17 / 17
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:38:20 UTC 2023` Edited by `admin` on `Sat Dec 16 11:38:20 UTC 2023`
Record UNII	F2D5P81X82
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ILS-920

Common Name

English

ILS 920

Code

English

WAY-265920

Code

English

3,4,9,10,13,14,15,16,18,21,22,23,24,25,26,27,32,33,34,34A-EICOSAHYDRO-9,27-DIHYDROXY-3-((1R)-2-((1S,3R,4R)-4-HYDROXY-3-METHOXYCYCLOHEXYL)-1-METHYLETHYL)-10,21-DIMETHOXY-6,8,12,14,20,26-HEXAMETHYL-16-PHENYL-23,27-EPOXY-15,18-ETHENOPYRIDO(2,1-R)(1,16,2,19)

Systematic Name

English

23,27-EPOXY-15,18-ETHENOPYRIDO(2,1-R)(1,16,2,19)DIOXADIAZACYCLOHENTRIACONTINE-1,5,11,28,29(6H,12H,31H)-PENTONE, 3,4,9,10,13,14,15,16,18,21,22,23,24,25,26,27,32,33,34,34A-EICOSAHYDRO-9,27-DIHYDROXY-3-((1R)-2-((1S,3R,4R)-4-HYDROXY-3-METHOXYCYCLOHEXYL)-1-ME

Systematic Name

English

Code System Code Type Description

PUBCHEM

58974612

Created by admin on Sat Dec 16 11:38:21 UTC 2023 , Edited by admin on Sat Dec 16 11:38:21 UTC 2023

PRIMARY

DRUG BANK

DB15422

Created by admin on Sat Dec 16 11:38:20 UTC 2023 , Edited by admin on Sat Dec 16 11:38:20 UTC 2023

PRIMARY

FDA UNII

F2D5P81X82

Created by admin on Sat Dec 16 11:38:20 UTC 2023 , Edited by admin on Sat Dec 16 11:38:20 UTC 2023

PRIMARY

CAS

892494-07-4

Created by admin on Sat Dec 16 11:38:20 UTC 2023 , Edited by admin on Sat Dec 16 11:38:20 UTC 2023

PRIMARY

SMS_ID

300000041430

Created by admin on Sat Dec 16 11:38:21 UTC 2023 , Edited by admin on Sat Dec 16 11:38:21 UTC 2023

PRIMARY

Related Record Type Details


					F2D5P81X82

ILS-920

ACTIVE MOIETY

Comments:

Originator: Wyeth; Developer: Pfizer; Class: Neuroprotectant; Mechanism of Action: Immunophilin inhibitor; Highest Development Phase: Discontinued for Stroke; Most Recent Event: 15 Oct 2009 Wyeth has been acquired by Pfizer.


					F2D5P81X82

ILS-920

ACTIVE MOIETY

Comments:

Immunophilin ligands, such as rapamycin, have potent neurotrophic activities in vitro, and have been implicated as potential treatments for stroke and Parkinson's disease. A brain-penetrant, nonimmuno-suppressive rapalog, ILS-920, has demonstrated a higher binding affinity to FKBP52 versus FKBP12. In a rat permanent middle cerebral artery occlusion (MCAO) model of stroke, ILS-920 reduces neurological deficits even when administered up to 24 hours post stroke, and this improvement in functional recovery is sustained for at least 90 days. Immuno-histochemical and cell culture analyses showed that ILS-920 protects neurons, oligodendrocytes, and astrocytes, reduces postischemic inflammatory responses and promotes expression of regenerative and oligodendrocyte maturation markers.